85290-80-8

Usage

Uses

Used in Organic Synthesis:
Ethyl 1-methyl-1H-pyrazole-4-carboxylate is used as a synthetic intermediate for the preparation of various organic compounds. Its carboxylate and pyrazole functionalities make it a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ethyl 1-methyl-1H-pyrazole-4-carboxylate is used as a key component in the development of new drugs. Its unique structure allows for the creation of molecules with potential therapeutic applications, such as anti-inflammatory, analgesic, or antimicrobial properties.
Used in Agrochemical Industry:
Ethyl 1-methyl-1H-pyrazole-4-carboxylate is employed as a starting material in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and structural features enable the design of novel compounds with improved efficacy and selectivity in controlling pests and weeds.
Used in Specialty Chemicals:
Ethyl 1-methyl-1H-pyrazole-4-carboxylate is utilized in the production of specialty chemicals, including dyes, pigments, and polymers. Its versatility in organic synthesis allows for the creation of compounds with specific properties, such as color, stability, or reactivity, which are valuable in various industrial applications.

Upstream product

• 540-80-7 tert.-butylnitrite 
• 5952-92-1 1-methyl-1H-pyrazole-4-carboxylic acid 
• 64-17-5 ethanol 
• 37622-90-5 4-ethoxycarbonylpyrazole 
• 74-88-4 methyl iodide 
• 80370-42-9 ethyl 2-formyl-3-oxopropanoate 
• 60-34-4 methylhydrazine 
• 31037-02-2 ethyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate 

Downstream Products

• 88398-82-7 ethyl 5-(chlorosulfonyl)-1-methyl-1H-pyrazole-4-carboxylate 
• 170020-91-4 1-methyl-1H-pyrazole-4-carboxylic acid hydrazide 
• 112029-98-8 (1-methyl-1H-pyrazol-4-yl)-methanol 
• 88398-81-6 ethyl 1-methyl-5-sulfamoyl-1H-pyrazole-4-carboxylate 
• 400877-05-6 (1‐methyl‐1H‐pyrazol‐4‐yl)methanamine 
• 735241-98-2 4-(chloromethyl)-1-methyl-1H-pyrazole 
• 56984-32-8 5-chloro-1-methyl-1H-pyrazole-4-carboxylic acid,ethyl ester 
• 1359029-60-9 ethyl 1-methyl-5-{[4-(trifluoromethyl)phenoxy]methyl}-1H-pyrazole-4-carboxylate 
• 1610343-53-7 1-(1',4-dimethyl-1-phenyl-1H,1'H-[3,4'-bipyrazol]-5-yl)-3-(1-methyl-1,2,3,4-tetrahydroquinolin-4-yl)urea 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

ATG7 INHIBITORS AND THE USES THEREOF

Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.(Formula I) (I)

Synthesis and characterization of novel pyridine associated 1,2,4-triazolo-1,3,4-thiadiazines

A series of novel 3-(1-methyl-1H-pyrazol-4-yl)-6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadaizine and its derivatives (8a-f) were synthesized by using 1-methyl-1H-pyrazole-4-carboxylic acid (3) as starting material and by involving 1-methyl-1H-pyrazole-

Direct C-H Alkenylation of Functionalized Pyrazoles

We have developed inter- and intramolecular C-H alkenylation reactions of pyrazoles. The catalyst, derived from Pd(OAc)2 and pyridine, enabled the oxidative alkenylation of pyrazoles containing a variety of functional groups at the C4 position.

BENZENE SULFONAMIDES AS CCR9 INHIBITORS

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which ca